Shares of AveXis Inc (NASDAQ:AVXS) have been given an average rating of “Buy” by the nine ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $93.83.
Several analysts have commented on the stock. Chardan Capital set a $103.00 price target on shares of AveXis and gave the stock a “buy” rating in a research note on Sunday. Jefferies Group LLC reiterated a “buy” rating and issued a $92.00 price target on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. assumed coverage on shares of AveXis in a research note on Tuesday, May 23rd. They issued a “buy” rating and a $90.00 price target on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $95.00 price target on shares of AveXis in a research note on Friday. Finally, Goldman Sachs Group, Inc. (The) boosted their price target on shares of AveXis from $91.00 to $108.00 and gave the stock a “buy” rating in a research note on Friday, March 17th.
In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Monday, May 1st. The shares were sold at an average price of $81.39, for a total value of $144,874.20. Following the sale, the vice president now owns 1,780 shares in the company, valued at approximately $144,874.20. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders sold 5,341 shares of company stock worth $406,682.
Hedge funds have recently made changes to their positions in the company. Nationwide Fund Advisors boosted its stake in shares of AveXis by 9.0% in the first quarter. Nationwide Fund Advisors now owns 3,444 shares of the company’s stock valued at $262,000 after buying an additional 284 shares in the last quarter. American International Group Inc. boosted its stake in shares of AveXis by 26.7% in the first quarter. American International Group Inc. now owns 3,521 shares of the company’s stock valued at $268,000 after buying an additional 742 shares in the last quarter. Swiss National Bank boosted its stake in shares of AveXis by 3.0% in the first quarter. Swiss National Bank now owns 27,400 shares of the company’s stock valued at $2,083,000 after buying an additional 800 shares in the last quarter. Teachers Advisors LLC boosted its stake in shares of AveXis by 2.6% in the first quarter. Teachers Advisors LLC now owns 54,217 shares of the company’s stock valued at $4,122,000 after buying an additional 1,387 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new stake in shares of AveXis during the first quarter valued at about $117,000. Institutional investors and hedge funds own 90.47% of the company’s stock.
Shares of AveXis (NASDAQ:AVXS) traded down 2.076% during midday trading on Tuesday, hitting $70.535. The company had a trading volume of 330,673 shares. The stock has a 50 day moving average price of $74.27 and a 200 day moving average price of $65.34. AveXis has a 1-year low of $31.55 and a 1-year high of $85.98. The firm’s market capitalization is $1.96 billion.
AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, May 11th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.13. During the same period last year, the firm posted ($1.24) EPS. On average, equities analysts anticipate that AveXis will post ($4.56) EPS for the current fiscal year.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc and related companies with MarketBeat.com's FREE daily email newsletter.